The Patent Finder
US

Aryl- and Heteroaryl-Substituted Tetrahydroisoquinolines and Use Thereof to Block Reuptake of Norepinephrine, Dopamine, and Serotonin

US 9,085,531 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended no later than Jul 15, 2025 · Medium confidence

Filed May 2, 2014 as application 14/268,753 · Granted Jul 21, 2015
Base term, 20 years from filing
Today
20 years from filing
Ended no later than Jul 15, 2025
2005 2026
Clock starts
Jul 15, 2005
Ended no later than
Jul 15, 2025
Granted
Jul 21, 2015
base term after the term ends fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jul 15, 2005, when application 11/183,066, the earliest non-provisional in its chain, was filed (this one was filed May 2, 2014)Jul 15, 2025High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer on file (approved), reference document not resolvedno cap applied, and none guessedMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderno later than Jul 15, 2025Medium confidence

This family

US 7,541,357Term ended
Nov 2026
Nov 2026
US 8,227,486Term ended
Nov 2026
Nov 2026
US 8,236,796Term ended
Nov 2026
Nov 2026
US 8,741,901Term ended
Jul 2025
Jul 2025
US 9,085,531this patent
no later than Jul 2025
no later than Jul 2025
US 9,499,531Term ended
Jul 2025
Jul 2025
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Oct 24, 2014
Reel 34045, frame 951
Albany Molecular Research, Inc.; Alo Acquisition LLC; Amri Burlington, Inc.; Amri Rensselaer, Inc.; Cedarburg Pharmaceuticals, Inc.; Oso Biopharmaceuticals Manufacturing, LLCBarclays Bank PLC, as the Collateral AgentSecurity Interest
Aug 5, 2015
Reel 36257, frame 914
Albany Molecular Research, Inc.; Amri Ssci, LLCBarclays Bank PLC, as the Collateral AgentSecurity Interest
Jun 22, 2016
Reel 39116, frame 827
Bristol-Myers Squibb CompanyAlbany Molecular Research, Inc.Assignment of Assignor's Interest
Aug 31, 2017
Reel 43742, frame 85
Barclays Bank PLC, as Collateral AgentAlbany Molecular Research, Inc.; Alo Acquisition LLC; Amri Burlington, Inc.; Amri Rensselaer, Inc.; Cedarburg Pharmaceuticals, Inc.; Oso Biopharmaceuticals Manufacturing, LLC; Amri Ssci, LLC; Euticals Inc.Release of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentAlbany Molecular Research, Inc.Release of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentAlo Acquisition LLCRelease of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentAmri Burlington, Inc.Release of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentAmri Rensselaer, Inc.Release of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentCedarburg Pharmaceuticals, Inc.Release of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentOso Biopharmaceuticals Manufacturing, LLCRelease of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentAmri Ssci, LLCRelease of Security Interest
Aug 31, 2017
reel/frame not recorded
Barclays Bank PLC, as Collateral AgentEuticals Inc.Release of Security Interest
Sep 1, 2017
Reel 43746, frame 621
Albany Molecular Research, Inc.; Amri Burlington, Inc.; Cedarburg Pharmaceuticals, Inc.; Euticals Inc.; Oso Biopharmaceuticals Manufacturing, LLC-by Its Sole Member: Alo Acquisition LLCBarclays Bank, PLC as Collateral AgentFirst Lien Security Agreement
Sep 1, 2017
Reel 43746, frame 657
Albany Molecular Research, Inc.; Amri Burlington, Inc.; Cedarburg Pharmaceuticals, Inc.; Euticals Inc.; Oso Biopharmaceuticals Manufacturing LLC-by Its Sole Member:alo Acquisition LLCMorgan Stanley Senior Funding, Inc.Second Lien Security Agreement
Aug 14, 2018
Reel 46796, frame 352
Albany Molecular Research, Inc.; Alo Acquisition LLC; Amri Burlington, Inc.; Amri Rensselaer, Inc.; Cedarburg Pharmaceuticals, Inc.; Oso Biopharmaceuticals Manufacturing, LLCBarclays Bank PLC, as the Collateral AgentCorrective Assignment to Correct the Incorrect Patent No. 7541537 Previously Recorded at Reel: 034045 Frame: 0951. Assignor(S) Hereby Confirms the Security Interest.
Oct 29, 2020
Reel 54252, frame 687
Morgan Stanley Senior Funding, Inc., as Collateral AgentAlbany Molecular Research, Inc.; Amri Burlington, Inc.; Cedarburg Pharmaceuticals, Inc.; Euticals Inc.; Oso Biopharmaceuticals Manufacturing, LLCRelease of Security Interest
Oct 29, 2020
reel/frame not recorded
Morgan Stanley Senior Funding, Inc., as Collateral AgentAlbany Molecular Research, Inc.Release of Security Interest
Oct 29, 2020
reel/frame not recorded
Morgan Stanley Senior Funding, Inc., as Collateral AgentAmri Burlington, Inc.Release of Security Interest
Oct 29, 2020
reel/frame not recorded
Morgan Stanley Senior Funding, Inc., as Collateral AgentCedarburg Pharmaceuticals, Inc.Release of Security Interest
Oct 29, 2020
reel/frame not recorded
Morgan Stanley Senior Funding, Inc., as Collateral AgentEuticals Inc.Release of Security Interest
Oct 29, 2020
reel/frame not recorded
Morgan Stanley Senior Funding, Inc., as Collateral AgentOso Biopharmaceuticals Manufacturing, LLCRelease of Security Interest
Nov 16, 2020
Reel 54382, frame 326
Barclays Bank PLC, as Collateral AgentAlbany Molecular Research, Inc.Release of Security Interest
Mar 7, 2025
Reel 70442, frame 908
Curia Global, Inc.; Curia IP Holdings, LLC; Curia Bio, Inc.Apollo Administrative Agency LLCSecurity Interest
May 20, 2025
Reel 71298, frame 97
Albany Molecular Research, Inc.Curia Global, Inc.Change of Name
Jun 3, 2025
Reel 71490, frame 880
Apollo Administrative Agency LLCCuria Global, Inc.Partial Release of First Lien Intellectual Property Security Agreement Supplement

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited